Generon (Shanghai) Corporation
Therapeutic recombinant proteins for cancer and autoimmune diseases
About Generon (Shanghai) Corporation
Generon (Shanghai) Corporation, which rebranded to Evive Biotech in June 2020, is a biotechnology company focused on developing novel biological therapeutics. Founded in 2004, the firm develops treatments for oncology and inflammatory disorders that are difficult to treat. The company's business model revolves around discovering, developing, and producing biomedicines, specifically therapeutic recombinant proteins, using advanced biotechnologies. It operates with a global outlook, aiming to serve both Chinese domestic and international markets by providing high-quality, affordable biomedicines that meet the regulatory standards of the SFDA, FDA, and EMA.
The company has established cGMP facilities and has operations in the United States, Singapore, and China. Its pipeline includes F-627, a treatment for chemotherapy-induced neutropenia (CIN), and F-652, which is being developed for alcoholic hepatitis (AH) and acute graft-versus-host disease (GVHD). In 2019, the U.S. FDA granted orphan drug status to F-652. In 2021, Evive Biotech and Dr. Xiaoqiang Yan formed a joint venture, ITabMed Ltd., to continue the development of products from the iTAb™ (immunotherapy antibody) platform, which focuses on creating bi- or tri-specific T cell engagers with improved safety profiles.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jun 2022 | $70M | $280M | Sino Biopharmaceutical · Yifan Pharmaceutical | ↗ |
Growth signals
Latest recorded traffic for Generon (Shanghai) Corporation is 430 monthly website visits, up 760% over the last three months. Generon (Shanghai) Corporation's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Generon (Shanghai) Corporation in the Huangpu ecosystem
The Generon (Shanghai) Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Sino Biopharmaceutical
Yifan Pharmaceutical
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Generon (Shanghai) Corporation on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Generon (Shanghai) Corporation’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










